{'52WeekChange': 0.7564461,
 'SandP52WeekChange': 0.0644362,
 'address1': '5320 Legacy Drive',
 'algorithm': None,
 'annualHoldingsTurnover': None,
 'annualReportExpenseRatio': None,
 'ask': 166.72,
 'askSize': 800,
 'averageDailyVolume10Day': 147725,
 'averageVolume': 346328,
 'averageVolume10days': 147725,
 'beta': 2.032529,
 'beta3Year': None,
 'bid': 157.21,
 'bidSize': 800,
 'bookValue': 6.879,
 'category': None,
 'circulatingSupply': None,
 'city': 'Plano',
 'companyOfficers': [],
 'country': 'United States',
 'currency': 'USD',
 'dateShortInterest': 1593475200,
 'dayHigh': 158.61,
 'dayLow': 153.91,
 'dividendRate': None,
 'dividendYield': None,
 'earningsQuarterlyGrowth': None,
 'enterpriseToEbitda': -14.77,
 'enterpriseToRevenue': 237.349,
 'enterpriseValue': 4770724864,
 'exDividendDate': None,
 'exchange': 'NGM',
 'exchangeTimezoneName': 'America/New_York',
 'exchangeTimezoneShortName': 'EDT',
 'expireDate': None,
 'fiftyDayAverage': 156.992,
 'fiftyTwoWeekHigh': 257.965,
 'fiftyTwoWeekLow': 70,
 'fiveYearAverageReturn': None,
 'fiveYearAvgDividendYield': None,
 'floatShares': 25759295,
 'forwardEps': -10.47,
 'forwardPE': -15.029608,
 'fromCurrency': None,
 'fullTimeEmployees': 220,
 'fundFamily': None,
 'fundInceptionDate': None,
 'gmtOffSetMilliseconds': '-14400000',
 'heldPercentInsiders': 0.052410003,
 'heldPercentInstitutions': 0.82027,
 'industry': 'Biotechnology',
 'isEsgPopulated': False,
 'lastCapGain': None,
 'lastDividendValue': None,
 'lastFiscalYearEnd': 1577750400,
 'lastMarket': None,
 'lastSplitDate': None,
 'lastSplitFactor': None,
 'legalType': None,
 'logo_url': 'https://logo.clearbit.com/reatapharma.com',
 'longBusinessSummary': 'Reata Pharmaceuticals, Inc., a clinical stage '
                        'biopharmaceutical company, develops novel '
                        'therapeutics for patients with serious or '
                        'life-threatening diseases by targeting molecular '
                        'pathways that regulate cellular metabolism and '
                        'inflammation. The company is developing Phase III '
                        'clinical trial programs, including bardoxolone methyl '
                        '(bardoxolone) for the treatment of patients with '
                        'chronic kidney disease(CKD) caused by Alport '
                        'syndrome, as well as for a form of pulmonary arterial '
                        'hypertension associated with connective tissue '
                        'disease; omaveloxolone that is Phase II clinical '
                        "trial to treat Friedreich's ataxia; and conduct phase "
                        '2 study for various form of CKD, such as IgA '
                        'nephropathy, type 1 diabetic, and focal segmental '
                        'glomerulosclerosis. It is also developing RTA 901, '
                        'which completed Phase 1 clinical trials for the '
                        'treatment of neurological diseases, such as diabetic '
                        'neuropathy; and RORgT Inhibitors that are in the '
                        'preclinical development phase for the potential '
                        'treatment of a range of autoimmune, inflammatory, and '
                        'fibrotic diseases. In addition, the company offers '
                        'bardoxolone for the treatment of Autosomal Dominant '
                        'Polycystic Kidney Disease (ADPKD), as well as '
                        'initiated phase 3 Falcon trial for the treatment of '
                        'ADPKD. Further, it has a strategic collaboration '
                        'agreement with Kyowa Kirin Co., Ltd. to develop and '
                        'commercialize bardoxolone for renal, cardiovascular, '
                        'diabetes, and various other related metabolic '
                        'indications in Japan, China, Hong Kong, Macao, South '
                        'Korea, Taiwan, Thailand, Singapore, the Philippines, '
                        'Malaysia, Indonesia, Brunei, Vietnam, Laos, Myanmar, '
                        'and Cambodia; and AbbVie Inc. to jointly research, '
                        'develop, and commercialize all second- and '
                        'later-generation Nrf2 activators for all indications '
                        'other than renal, cardiovascular, and metabolic '
                        'indications. The company was formerly known as Reata '
                        'Discovery, Inc. and changed its name to Reata '
                        'Pharmaceuticals, Inc. in May 2005. Reata '
                        'Pharmaceuticals, Inc. was founded in 2002 and is '
                        'headquartered in Plano, Texas.',
 'longName': 'Reata Pharmaceuticals, Inc.',
 'market': 'us_market',
 'marketCap': 5283865600,
 'maxAge': 1,
 'maxSupply': None,
 'messageBoardId': 'finmb_6966894',
 'morningStarOverallRating': None,
 'morningStarRiskRating': None,
 'mostRecentQuarter': 1585612800,
 'navPrice': None,
 'netIncomeToCommon': -309955008,
 'nextFiscalYearEnd': 1640908800,
 'open': 155.54,
 'openInterest': None,
 'payoutRatio': 0,
 'pegRatio': None,
 'phone': '972 865 2219',
 'previousClose': 156.71,
 'priceHint': 2,
 'priceToBook': 22.875418,
 'priceToSalesTrailing12Months': 262.87888,
 'profitMargins': 0,
 'quoteType': 'EQUITY',
 'regularMarketDayHigh': 158.61,
 'regularMarketDayLow': 153.91,
 'regularMarketOpen': 155.54,
 'regularMarketPreviousClose': 156.71,
 'regularMarketPrice': 155.54,
 'regularMarketVolume': 132154,
 'revenueQuarterlyGrowth': None,
 'sector': 'Healthcare',
 'sharesOutstanding': 28508000,
 'sharesPercentSharesOut': 0.1058,
 'sharesShort': 3551443,
 'sharesShortPreviousMonthDate': 1590710400,
 'sharesShortPriorMonth': 3485742,
 'shortName': 'Reata Pharmaceuticals, Inc.',
 'shortPercentOfFloat': 0.1696,
 'shortRatio': 6.27,
 'startDate': None,
 'state': 'TX',
 'strikePrice': None,
 'symbol': 'RETA',
 'threeYearAverageReturn': None,
 'toCurrency': None,
 'totalAssets': None,
 'tradeable': False,
 'trailingAnnualDividendRate': None,
 'trailingAnnualDividendYield': None,
 'trailingEps': -9.915,
 'twoHundredDayAverage': 169.75633,
 'volume': 132154,
 'volume24Hr': None,
 'volumeAllCurrencies': None,
 'website': 'http://www.reatapharma.com',
 'yield': None,
 'ytdReturn': None,
 'zip': '75024'}